ENFLEUR is pleased to share Zynerba Pharmaceuticals’ announcement that it is moving into the second phase of trials with Zygel™, a CBD transdermal gel, in order to assess the drug’s efficacy, tolerability, and safety. There are currently two FDA approved products indicated to treat ASD symptoms, however they have a significant side effects and have not been approved to treat some of the more difficult symptoms of ASD, social impairment and anxiety. Recent studies indicate a possible relationship between the symptoms of ASD and disfunction in the endocannabinoid system. Additionally, “[c]linical and anecdotal data suggest that CBD may modulate the [endocannabinoid] system and improve certain core social and behavioral autism-related symptoms, including social avoidance and anxiety.”
Outside of Zynerba Pharmaceuticals’ current efforts,CBD has shown itself to be generally well-tolerated at up to 1,500mg a day, and studies have also shown CBD’s therapeutic potential in the treatment of a variety of anxiety disorders. A high quality, transparent CBD product is a meaningful consideration when evaluating a wellness regime.
ENFLEUR will continue to follow developments as Zygel™ progresses through trials.
Why does this matter? With ASD possibly linked to endocannabinoid system disfunction, the investigation of CBD’s pharmaceutical potential to alleviate ASD symptoms progresses.